The brain cancer diagnostics market in South and Central America is expected to grow from US$ 69.7 million in 2021 to US$ 175.8 million by 2028; it is estimated to grow at a CAGR of 14.1% from 2021 to 2028.
Currently, there is insufficient evidence that they are less harmful than traditional cigarettes. Researchers at Wake Forest School of Medicine have discovered that nicotine promotes the spread of lung cancer cells to the brain, thereby forming deadly metastatic tumors. The study, published in the Journal of Experimental Medicine (JEM), suggests that nicotine replacement therapy may not be suitable for lung cancer patients trying to quit smoking. Thus, the increase in the number of cigarette smokers is bolstering the growth of the brain cancer diagnostics market. The COVID‐ 19 pandemic is a critical test for the already overburdened and underfunded public healthcare systems of South and Central America. It suffers from severe inequalities. With a vast population living in poverty, South and Central America continuously face widespread health problems due to overcrowding, limited sanitation, food insecurity, and unpredictable environmental conditions. Underfunded state‐run hospitals are the only source of medical care in the region. Brazil is in a critical situation due to COVID-1. Lack of resources is creating more challenges in the region, hampering the growth of the brain cancer diagnostics market. All these factors will restrict the distribution and adoption of diagnostics products and services which will restrict the market growth. However, as the vaccination continues to these countries, the various market players in this region will again start focusing on development of brain cancer diagnostics and increase their distribution of products. Hence impact of pandemic will become moderated on the brain cancer diagnostics market.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the brain cancer diagnostics market. The South and Central America brain cancer diagnostics market is expected to grow at a good CAGR during the forecast period.
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
South and Central America Brain Cancer Diagnostics Market Segmentation
By Diagnostic Type
- Imaging Test
- MRI
- CT Scan
- PET
- Biopsy
- Molecular Testing
- Lumbar Puncture
- Others
By Cancer Type
- Glioblastoma Multiforme
- Astrocytomas
- Ependymomas
- Others
By End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others
By Country
- South and Central America
- Brazil
- Argentina
- Rest of South and Central America
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Siemens Healthineers A
- GE Healthcare
- Biocept, Inc.
- Koninklijke Philips N.V
- Canon Medical Systems
- Hitachi, Ltd.
- Neusoft Medical Systems
South and Central America Brain Cancer Diagnostics Report Scope
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 69.7 Million |
Market Size by 2028 | US$ 175.8 Million |
Global CAGR (2021 - 2028) | 14.1% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By Diagnostic Type
|
Regions and Countries Covered | South and Central America
|
Market leaders and key company profiles |
|
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Recent Reports
Testimonials
Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Identifying Emerging Markets
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Boosting Operational Efficiency
- Strategic Planning
- Investment Justification
- Tracking Industry Innovations
- Aligning with Regulatory Trends

















